| Literature DB >> 31657232 |
Neil Henderson1, Amanda Wilson2.
Abstract
The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for the pharmaceutical industry and contract research organizations. This article describes some of the challenges and strategies for performing regulated bioanalysis of modified mRNA therapeutics by comparing the two main analytical approaches - quantitative reverse transcription PCR and branched DNA.Keywords: branched DNA (bDNA); modified messenger RNA (mRNA); quantitative reverse transcription PCR (qRT-PCR); regulatory bioanalysis
Mesh：
Substances：
Year: 2019 PMID： 31657232 DOI： 10.4155/bio-2019-0120
Source DB: PubMed Journal: Bioanalysis ISSN： 1757-6180 Impact factor: 2.681